BioCentury | May 13, 2019
Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

...blood vessels. Daromun combines Darleukin, which fuses IL-2 with an L19 human mAb fragment targeting FnEDB...
...Fibronectin extra ED-B domain isoform; IL-2 - Interleukin-2; TNF - Tumor necrosis factor Elizabeth S. Eaton, Staff Writer. Daromun (L19IL2/L19TNF) Fibromun (L19-TNF) Philogen S.p.A. Fibronectin extra ED-B domain isoform (FnEDB) (oncofetal fibronectin) Interleukin-2...
BioCentury | May 6, 2019
Distillery Therapeutics

CAR Ts targeting PD-L1, FnEDB for three solid tumor types

...colorectal cancer; melanoma Cell culture and mouse studies suggest CAR T cells targeting PD-L1 or FnEDB...
...models, anti-FnEDB CAR T cells decreased tumor growth and increased survival. Also in the model, anti-FnEDB...
...the three cancers. TARGET/MARKER/PATHWAY: Programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274); fibronectin extra ED-B domain isoform (FnEDB; oncofetal fibronectin...
BioCentury | Mar 2, 2018
Product Development

Clever pegylation pay off

...S.p.A. Darleukin (A) Fusion of IL-2 and L19, a human mAb fragment targeting fibronectin extra ED-B domain isoform (FnEDB; oncofetal fibronectin...
BioCentury | Jul 10, 2017
Distillery Therapeutics

Cancer

...a fusion of IL-2 and L19, a human mAb fragment targeting fibronectin extra ED-B domain isoform ( FnEDB ; oncofetal fibronectin...
BioCentury | Apr 27, 2015
Emerging Company Profile

Go-ing sugar specific

...cells. Go also has preclinical mAbs against mucin 4 (MUC4) and fibronectin extra ED-B domain isoform ( FnEDB ; oncofetal fibronectin...
BioCentury | May 9, 2005
Clinical News

AngioMab: Phase I halted

...Product: AngioMab (AS1405) Business: Cancer Molecular target: Not available Description: Radiolabeled antibody that binds to oncofetal fibronectin...
BioCentury | Aug 2, 2004
Company News

Antisoma, Merck KGaA deal

...IL-12 in cancer by using BC1 to deliver it directly to tumor tissue. BC1 targets oncofetal fibronectin...
BioCentury | Jul 26, 2004
Company News

Antisoma acquires full rights to BC1-IL12

...huBC1 antibody and EMD's immunocytokine technology to deliver interleukin-12 (IL-)12 directly to tumors. BC1 targets oncofetal fibronectin...
BioCentury | Nov 3, 1997
Company News

Cambridge Centre for Protein Engineering other research news

...of cancers. Cambridge Centre for Protein Engineering , Cambridge, U.K., et al. Product: Antibodies against oncofetal fibronectin...
Items per page:
1 - 9 of 9